Sirtuin modulating compounds

Details Sirtuin modulating compounds Sirtuin modulating compounds

2006-08-04

2010-12-21

Havlin, Robert (Department: 1626)

Organic compounds -- part of the class 532-570 series

Organic compounds

Four or more ring nitrogens in the bicyclo ring system

C514S249000

Reexamination Certificate

active

07855289

ABSTRACT:
Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benfit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

REFERENCES:
patent: 3164603 (1965-01-01), McCafferty
patent: 3503929 (1970-03-01), Loudas
patent: 3517007 (1970-06-01), Kim et al.
patent: 3712888 (1973-01-01), Kaempfen
patent: 3928228 (1975-12-01), Crounse
patent: 4038396 (1977-07-01), Shen et al.
patent: 4189321 (1980-02-01), Kojima et al.
patent: 4471040 (1984-09-01), Katagiri et al.
patent: 4939133 (1990-07-01), Connor et al.
patent: 5808087 (1998-09-01), Matsunaga et al.
patent: 5814651 (1998-09-01), Duplantier et al.
patent: 5852011 (1998-12-01), Matsunaga et al.
patent: 5958950 (1999-09-01), Padia et al.
patent: 6291476 (2001-09-01), Kordik et al.
patent: 6479508 (2002-11-01), Beaulieu et al.
patent: 6653309 (2003-11-01), Saunders et al.
patent: 7345178 (2008-03-01), Nunes et al.
patent: 2003/0199516 (2003-10-01), Moser et al.
patent: 2003/0232816 (2003-12-01), Beaulieu et al.
patent: 2004/0010033 (2004-01-01), Anderson et al.
patent: 2004/0034037 (2004-02-01), Harbeson et al.
patent: 2004/0044203 (2004-03-01), Wittman et al.
patent: 2004/0048843 (2004-03-01), Ting et al.
patent: 2004/0072760 (2004-04-01), Carboni et al.
patent: 2004/0142997 (2004-07-01), Chen et al.
patent: 2004/0152743 (2004-08-01), Schoenafinger et al.
patent: 2004/0157845 (2004-08-01), Doherty et al.
patent: 2004/0171073 (2004-09-01), Neiland et al.
patent: 2004/0180905 (2004-09-01), Munchhof
patent: 2004/0220189 (2004-11-01), Sun et al.
patent: 2005/0009840 (2005-01-01), Cui et al.
patent: 2005/0065151 (2005-03-01), Norcross
patent: 2005/0065196 (2005-03-01), Inaba et al.
patent: 2005/0085519 (2005-04-01), Rubin et al.
patent: 2005/0197353 (2005-09-01), Ritzeler et al.
patent: 2005/0197375 (2005-09-01), Sircar et al.
patent: 2005/0245513 (2005-11-01), Gallant et al.
patent: 2005/0266515 (2005-12-01), O'Brien et al.
patent: 2006/0014756 (2006-01-01), Edwards et al.
patent: 2006/0036098 (2006-02-01), Kim et al.
patent: 2006/0074075 (2006-04-01), Hadida-Ruah et al.
patent: 2007/0037809 (2007-02-01), Nunes et al.
patent: 2007/0037810 (2007-02-01), Nunes et al.
patent: 2007/0037827 (2007-02-01), Nunes et al.
patent: 2007/0037865 (2007-02-01), Nunes et al.
patent: 2009/0099170 (2009-04-01), Nunes et al.
patent: 2009/0163476 (2009-06-01), Milburn et al.
patent: 093289 (1989-09-01), None
patent: 2330109 (1974-01-01), None
patent: 1460067 (2004-09-01), None
patent: 1439129 (1966-05-01), None
patent: 1476529 (1967-04-01), None
patent: 1382861 (1975-02-01), None
patent: 1421619 (1976-01-01), None
patent: 2405793 (2005-03-01), None
patent: 41006584 (1966-04-01), None
patent: 04190232 (1992-07-01), None
patent: 06247969 (1994-09-01), None
patent: 2002161084 (2002-06-01), None
patent: 2003/300875 (2003-10-01), None
patent: 2003/300886 (2003-10-01), None
patent: 2003/313176 (2003-11-01), None
patent: 2004/75614 (2004-11-01), None
patent: 2005/162855 (2005-06-01), None
patent: 2005/330284 (2005-12-01), None
patent: 96241 (1977-12-01), None
patent: WO 97/04776 (1997-02-01), None
patent: WO 99/33824 (1999-07-01), None
patent: WO 00/69849 (2000-11-01), None
patent: WO 01/00610 (2001-01-01), None
patent: WO 01/21615 (2001-03-01), None
patent: WO 01/27119 (2001-04-01), None
patent: WO 01/96336 (2001-12-01), None
patent: WO 02/066454 (2002-08-01), None
patent: WO 02/079192 (2002-10-01), None
patent: WO-03/007959 (2003-01-01), None
patent: WO-03/011219 (2003-02-01), None
patent: WO 03/066629 (2003-08-01), None
patent: WO 03/074516 (2003-09-01), None
patent: WO 03/080545 (2003-10-01), None
patent: WO-2004/016600 (2004-02-01), None
patent: WO 2004/030625 (2004-04-01), None
patent: WO 2004/033666 (2004-04-01), None
patent: WO 2004/039318 (2004-05-01), None
patent: WO 2004/041277 (2004-05-01), None
patent: WO 2004/062663 (2004-07-01), None
patent: WO 2004/069160 (2004-08-01), None
patent: WO 2004/084813 (2004-10-01), None
patent: WO 2005/002552 (2005-01-01), None
patent: WO 2005/025574 (2005-03-01), None
patent: WO 2005/043630 (2005-05-01), None
patent: WO 2005/077939 (2005-08-01), None
patent: WO-2005/100342 (2005-10-01), None
patent: WO 2005/105798 (2005-11-01), None
patent: WO-2006/018280 (2006-02-01), None
patent: WO-2006/020767 (2006-02-01), None
patent: WO 2006/034833 (2006-04-01), None
patent: WO 2006/050506 (2006-05-01), None
patent: WO-2006/053227 (2006-05-01), None
patent: WO-2006/094236 (2006-09-01), None
patent: WO 2006/113458 (2006-10-01), None
patent: WO-2007/019344 (2007-02-01), None
patent: WO 2007/019346 (2007-02-01), None
patent: WO 2008/073451 (2008-06-01), None
patent: WO-2008/106692 (2008-09-01), None
patent: WO 2008/156869 (2008-12-01), None
Kubinyi (3D QSAR in Drug Design: Ligand-Protein Interactions and Molecular Similarity, vol. 2-3, Springer, 1998, 800 pages), p. 243-44 provided.
Barraclough, et al., “Inotropic activity of heterocyclic analogues of isomazole,”European Journal of Medicinal Chemistry,25:467-477 (1990).
Porcu, et al., “The emerging therapeutic potential of sirtuin-interacting drugs: from cell death to lifespan extension,” TRENDS in Pharmacological Sciences, 26(2):94-103 (2005).
Database Chemcats Chemical Abstracts Service, Columbus, OH, US; Jan. 18, 2005, XP002384121 ON's STK199474, STK199472, STK199473, STK180355, STK174405, STK196060, STK115373, STK164162, STK136073, STK164152, STK120473, STK052285 -& “Interchim Intermediates” Jan. 18, 2005, Interchim, Montlucon, France, XP002386059.
Jules et al., “Derivatives of 3-, 4-, and 5-Phenylsalicylamides”J. Am. Pharma. Assoc.,45(5):277-281, (1956).
Yogi et al., “Synthesis of Arylthio-Substituted 3,8-Diphenyl-1,2-diazacycloocta-2,4,6,8-tetraenes and Their Thermolysis”Bull. Chem. Soc. Jpn,60(1):335-342 (1987).
Attanasi, et al., “Conjugated Azoalkenes. Part 14. Synthesis of New 1-Amino-and 1,2-Diamino-pyrrole Derivatives by Reaction of some Conjugated Azoalkenes with Activated Methylene Compounds RCH2Ac and RCH2CN (R = Aryl, Heteroaryl),” Journal of the Chemical Society, Perkin Transactions 1, Organic and Bioorganic Chemistry, 3:315-320 (1993).
Bamford et al., “(1H-Imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: A novel class of potent MSK-1-inhibitors,” Bioorganic and Medicinal Chemistry Letters, 15:3402-06 (2005).
Bauser et al., “Discovery and optimization of 2-aryl oxazolo-pyrimidines as adenosine kinase inhibitors using liquid phase parallel synthesis,” Bioorganic & Medicinal Chemistry Letters, 14:1997-2000 (2004).
Borra et al., “Mechanism of Human SIRT1 Activation by Resveratrol”, J. Biol. Chem., 280(17):17187-195 (2005).
Brandon et al., “Monoclonal Antibody-Based ELISA for Thiabendazole in Liver,” Journal of Agric. Food Chem., 40:1722-26 (1992).
Briehn et al., “Alternative heterocycles for DNA recognition: The benzimidazole/imidazole pair,” Chemistry-A European Journal, 9(9):2110-22 (2003).
Bukowski “Some reactions of 2-cyanobenzimidazoles,” Acta Poloniae Pharmaceutica, 35(3):295-299 (1978) (abstract only).
Bürli et al., “DNA binding ligands targeting drug-resistant Gram-positive bacteria. Part 1: Internal benzimidazole derivatives,” Bioorganic and Medicinal Chemistry Letters, 14(5):1253-57 (2004).
Bürli et al., “DNA binding ligands targeting drug-resistant Gram-positive bacteria. Part 2: C-terminal benzimidazole and derivatives,” Bioorganic and Medicinal Chemistry Letters, 14(5):1259-63 (2004).
Dahlbom et al.,

Affiliated with

Also associated with

Rating

Sirtuin modulating compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Sirtuin modulating compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sirtuin modulating compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4166093